Docetaxel has recently been shown to improve survival in hormone-independent prostate cancer with distant metastases (AIPC Androgen-independent Prostate Cancer). Chemotherapy as a first-line treatment option currently has significant upside, while there are more options for second-line treatment but with mixed results. A review of the literature on chemotherapy regimens for advanced prostate cancer and their mechanisms, efficacy, and effects in recent years shows that docetaxel is currently the standard chemotherapy agent for distant metastatic hormone-independent prostate cancer (AIPC). Several clinical studies have shown that in combination with docetaxel or as a second-line combination regimen, osteopontin, sarcosamine, bevacizumab, satraplatin, vaccine, Ixebepilone, and Atrasentan have shown good therapeutic efficacy and therapeutic promise. Therefore, docetaxel is considered as the current first-line therapeutic agent for the treatment of metastatic AIPC. However, as its disease-free progression time is usually only 6 months, more effective drugs or combination approaches are currently under further clinical investigation. What is certain: docetaxel in combination with other new antineoplastic agents is highly promising in the treatment of metastatic AIPC. Prostate cancer, currently, is the most common malignancy in men in the United States. More than 200,000 new cases occur each year, and nearly 27,000 patients died of prostate cancer nationwide in 2007. Prior to metastasis, most patients are initially treated with medication or surgical debulking to suppress androgen levels. In patients with progressive prostate cancer, anti-androgen therapy significantly reduces PSA (prostate-specific antigen) levels, soft tissue and bone metastases. Since bone metastases occur in more than 85% of patients, the ideal and rational treatment should cover both primary lesions and metastases. When metastases develop with disease progression, second-line hormonal therapy or systemic chemotherapy is usually chosen. The results of previous reports on chemotherapy for prostate cancer have been mixed, with early clinical studies showing that the ideal outcome of chemotherapy tends to be stabilization and symptomatic improvement, but no improvement in survival. The effectiveness of PSA has been in the 20-30% range, with median survival of no more than 12 months, and most of them have progressed to hormone-independent prostate cancer. In the past few years, most chemotherapeutic agents have been used for palliative treatment, and given their stability in palliative care, the US FDA approved mitoxantrone in combination with prednisone for the treatment of metastatic AIPC, but it did not have an advantage in terms of improvement in survival. This article reviews the combination chemotherapy regimens on metastatic AIPC in recent years. Docetaxel: first-line chemotherapy for metastatic AIPC The US FDA recently approved docetaxel for the treatment of metastatic AIPC. two landmark clinical trials, SWOG-9916 and TAX327, showed that the treatment of advanced metastatic AIPC with docetaxel significantly prolonged the survival time of patients. The trials enrolled 674 patients with metastatic AIPC, one group receiving docetaxel in combination with estradiol nitrogen mustard chemotherapy and the other group receiving mitoxantrone in combination with prednisone. The results showed that there was a significant improvement in survival, time to disease progression, and PSA efficiency in the docetaxel-estradiol mustard chemotherapy group. This combination regimen was also superior to the mitoxantrone combined with prednisone group in terms of median survival time (17.5 months versus 15.6 months, P=0.02).